Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Messenger RNA

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Messenger RNA. Displaying page 1 of 1.
    EudraCT Number: 2009-012350-20 Sponsor Protocol Number: MSC-KTx Start Date*: 2008-01-14
    Sponsor Name:AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" (A.O. DI RILIEVO NAZIONALE)
    Full Title: MESENCHYMAL STEM CELLS UNDER BASILIXIMAB/ LOW DOSE RATG TO INDUCE RENAL TRANSPLANT TOLERANCE
    Medical condition: Patients will be those receiving a living-related kidney transplant
    Disease: Version SOC Term Classification Code Term Level
    15.1 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001693-33 Sponsor Protocol Number: ITL-2002-CL-001 Start Date*: 2022-03-30
    Sponsor Name:Intellia Therapeutics, Inc.
    Full Title: Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults with Hereditary Angioedema (HAE)
    Medical condition: Hereditary Angioedema
    Disease: Version SOC Term Classification Code Term Level
    23.1 10010331 - Congenital, familial and genetic disorders 10019860 Hereditary angioedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002927-39 Sponsor Protocol Number: BOOST_TX/RESCUE_TX Start Date*: 2021-06-13
    Sponsor Name:Medical University of Vienna
    Full Title: Preventive strategies against SARS-CoV-2 in kidney transplant recipients: Intervention A – vaccination: Single blinded randomized controlled trial on BNT162b2 or mRNA-1273 (mRNA) vs Ad26COVS1 or C...
    Medical condition: Intervention A - vaccination Patients following kidney transplant recipients who do not have an adequate immune response against SARS-CoV-2 following two doses of an mRNA vaccine Substudy A: kidne...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002542-33 Sponsor Protocol Number: ZYN2-CL-033 Start Date*: 2022-02-22
    Sponsor Name:Zynerba Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults with Fragile X Syndro...
    Medical condition: Fragile X syndrome (FXS) is a rare genetic disorder caused by the deficiency or absence of Fragile X Messenger Ribonucleoprotein 1 (FMRP), an RNA-binding protein and the gene product of the FMR1 ge...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002678-31 Sponsor Protocol Number: CA184-007 Start Date*: 2006-03-20
    Sponsor Name:BRISTOL-M.SQUIBB
    Full Title: Randomized, double-blind, placebo controlled phase II study comparing the safety of MDX-010 BMS-734016 administered with or without prophylactic oral budesonide Entocort EC in patients with unr...
    Medical condition: Melanoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10027156 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002246-41 Sponsor Protocol Number: BP29420 Start Date*: 2014-10-23
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO6885247 FOLLOWING 12 WEEKS OF T...
    Medical condition: Spinal Muscular Atrophy
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10041582 Spinal muscular atrophy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-001520-18 Sponsor Protocol Number: NL76839.042.21 Start Date*: 2021-04-09
    Sponsor Name:RECOVAC consortium
    Full Title: Long term efficacy and safety of SARS-CoV-2 vaccination in Dutch patients with chronic kidney disease stage G4-G5, on dialysis or after kidney transplantation
    Medical condition: COVID-19 is associated with increased morbidity and mortality in kidney transplant recipients (KTR) and patients with chronic kidneydisease (CKD). Therefore, potential efficacious SARS-CoV-2 vaccin...
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    23.1 10042613 - Surgical and medical procedures 10084464 COVID-19 immunization LLT
    23.1 10042613 - Surgical and medical procedures 10084465 COVID-19 vaccination LLT
    23.1 100000004848 10084508 COVID-19 antibody test LLT
    23.0 100000004862 10084270 SARS-CoV-2 acute respiratory disease LLT
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    23.0 10042613 - Surgical and medical procedures 10084462 SARS-CoV-2 vaccination LLT
    23.0 10042613 - Surgical and medical procedures 10084463 SARS-CoV-2 immunisation LLT
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    20.0 10042613 - Surgical and medical procedures 10023438 Kidney transplant LLT
    20.0 10042613 - Surgical and medical procedures 10061105 Dialysis PT
    20.0 10042613 - Surgical and medical procedures 10018875 Haemodialysis PT
    20.0 10042613 - Surgical and medical procedures 10034660 Peritoneal dialysis PT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    23.1 10038359 - Renal and urinary disorders 10076412 Chronic kidney disease stage 5 LLT
    23.1 10038359 - Renal and urinary disorders 10076411 Chronic kidney disease stage 4 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-004141-17 Sponsor Protocol Number: Start Date*: 2020-08-07
    Sponsor Name:Children's Oncology Group
    Full Title: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
    Medical condition: Ovarian, Testicular, or Extragonadal germ cell tumours
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015800 Extragonadal primary germ cell tumour mixed stage I PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015801 Extragonadal primary germ cell tumour mixed stage II PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015802 Extragonadal primary germ cell tumour mixed stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043331 Testicular germ cell tumour mixed stage I PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043332 Testicular germ cell tumour mixed stage II PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043333 Testicular germ cell tumour mixed stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004433 Benign ovarian tumour PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006032 Borderline ovarian tumour PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-001693-18 Sponsor Protocol Number: GED-0301-CD-005 Start Date*: 2016-01-29
    Sponsor Name:CELGENE CORPORATION
    Full Title: A Phase 2, Open-Label Study to Explore the Pharmacodynamic and Clinical Effects of Mongersen (GED-0301) in Subjects with Active Crohn's Disease
    Medical condition: Active Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10013099 Disease Crohns LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000795-15 Sponsor Protocol Number: MYVAC2 Start Date*: 2014-01-29
    Sponsor Name:UZ Brussel
    Full Title: An open-label pilot clinical trial of MAGE-A3 and MAGE-C1 mRNA electroporated autologous dendritic cell vaccination in combination with lenalidomide maintenance therapy for multiple myeloma after f...
    Medical condition: Symptomatic Multiple Myeloma after first-line autologous stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001764-36 Sponsor Protocol Number: ITACA Start Date*: 2008-08-13
    Sponsor Name:Azienda Ospedaliero Universitaria ''San Luigi Gonzaga''
    Full Title: Phase III Multicenter Randomized Trial Comparing Adjuvant Pharmacogenomic-Driven Chemotherapy versus Standard Adjuvant Chemotherapy in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer.
    Medical condition: patients with completely resected Stage II-IIIA non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005488-18 Sponsor Protocol Number: 8628-006 Start Date*: 2016-05-12
    Sponsor Name:Oncoethix GmbH, a wholly owned subsidiary of Merck Sharp & Dohme Corp.
    Full Title: A Phase IB Dose Exploration Trial with MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects with Selected Advanced Solid Tumors
    Medical condition: NUT Midline Carcinoma Non-Small Cell Lung Cancer Triple-Negative Breast Cancer Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-002994-39 Sponsor Protocol Number: Cx611-0204 Start Date*: 2016-04-06
    Sponsor Name:TIGENIX, S.A.U.
    Full Title: A phase Ib/IIa, randomised, double blind, parallel group, placebo controlled, multicentre study to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for...
    Medical condition: Severe community-acquired bacterial pneumonia requiring mechanical ventilation and/or vasopressors.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) LT (Completed) GB (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004321-86 Sponsor Protocol Number: RN5609C00 Start Date*: 2019-07-24
    Sponsor Name:BioNTech SE
    Full Title: First-in-human, dose titration and expansion trial to evaluate safety, immunogenicity and preliminary efficacy of W_pro1 (BNT112) monotherapy and in combination with cemiplimab in patients with pr...
    Medical condition: Male adults with prostate cancer, both mCRPC (Arms 1A & 1B) and LPC (ARms 2&3) patients, will be treated with W_pro1 alone or in combination with cemiplimab. LPC patients will also receive neo-adju...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007113 Cancer of prostate LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 15:05:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA